SI-BONE Stock

SI-BONE ROE

The Return on Equity (ROE) of SI-BONE (SIBN) as of Aug 22, 2026 is -10.65 %. In the previous year, Return on Equity (ROE) was -18.51 % — a change of -42.48% (higher).

ROE

-10.65 %

YoY

-42.48%

Last updated:

In 2026, SI-BONE's return on equity (ROE) was -10.65 %, a -42.48% increase from the -18.51 % ROE in the previous year.

The SI-BONE ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-19.35 USD
Jan 1, 2019
-60.95 USD
Jan 1, 2020
-25.80 USD
Jan 1, 2021
-42.09 USD
Jan 1, 2022
-62.31 USD
Jan 1, 2023
-25.59 USD
Jan 1, 2024
-18.51 USD
Jan 1, 2025
-10.65 USD
The SI-BONE ROE history
YEARROEYoY
-10.65 %-42.48%
-18.51 %-27.64%
-25.59 %-58.94%
-62.31 %+48.06%
-42.09 %+63.12%
-25.80 %-57.67%
-60.95 %+214.97%
-19.35 %-208.67%
17.81 %-5.96%
18.94 %-102.17%
-870.83 %+115.84%
-403.45 %—
Access this data via the Eulerpool API
Get Free API Key

SI-BONE Stock analysis

What does SI-BONE do? SI-BONE Inc. is an innovative medical technology company based in Santa Clara, California. It was founded in 2008 by a group of orthopedic surgeons, engineers, and entrepreneurs who aimed to improve the treatment of lower back pain. The company is now globally recognized and specializes in the development and marketing of implants for the treatment of pain and discomfort in the pelvic and back areas. SI-BONE focuses on the treatment of pain and discomfort in the pelvic and back areas, offering a range of products for this purpose. The company's main focus is on the development of innovative implants that can be used minimally invasively, with the goal of providing patients with quick recovery and improved quality of life. The flagship product of SI-BONE is the iFuse implant. This implant is used in patients with chronic lower back pain caused by instability of the spine or pelvis. The iFuse implant stabilizes the pelvis and thereby reduces the pain originating from the unstable joint region. The iFuse implant has been FDA approved and is now available in over 40 countries worldwide. In addition to the iFuse implant, SI-BONE also offers a variety of other products tailored to the needs of physicians and patients. These include implantable instruments and consumables such as bone screws or arthroscopy needles. SI-BONE is a publicly traded company listed on NASDAQ under the ticker symbol "SIBN." The company's business model is based on providing innovative products to physicians and hospitals that optimize the treatment of back pain. To achieve this, SI-BONE works closely with leading industry professionals to enable optimal treatment of back pain. SI-BONE has established itself as a strong, innovative company specializing in minimally invasive implants in the field of pain therapy. Through close collaboration with physicians and specialists and investment in research and development of cutting-edge technologies, SI-BONE aims to continue growing and achieve a leading position in the field of pain therapy. SI-BONE is one of the most popular companies on Eulerpool.

ROE Details

Decoding SI-BONE's Return on Equity (ROE)

SI-BONE's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing SI-BONE's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

SI-BONE's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in SI-BONE’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about SI-BONE stock

Return on Equity (ROE) of SI-BONE is -10.65 % in 2026.

Return on Equity (ROE) of SI-BONE changed from -18.51 % to -10.65 %, representing a -42.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) SI-BONE since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s SI-BONE with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — SI-BONE

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — SI-BONE